Neo Announces Voting Results from Annual General Meeting of Shareholders
TORONTO, June 26, 2025 /CNW/ - Neo Performance Materials Inc. (" Neo" or the " Company") (TSX: NEO) reports, in accordance with the policies of the Toronto Stock Exchange, the results of the matters put before shareholders for consideration and approving at the Company's annual general meeting of shareholders, as described in the management information circular dated May 21, 2025 are set out below. A total of 25.6 million common shares were voted in person or by proxy, representing 61.2% of the outstanding common shares.
Shareholders voted as follows:
Cautionary Statements Regarding Forward Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws in Canada. Forward-looking information may relate to future events or future performance of Neo. All statements in this news release, other than statements of historical facts, with respect to Neo's objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions are forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Neo believes the expectations reflected in such forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information included in this discussion and analysis should not be unduly relied upon. For more information on Neo, investors should review Neo's continuous disclosure filings available under its profile at www.sedarplus.ca. Information contained in forward-looking statements in this press release is provided as of the date hereof and Neo disclaims any obligation to update any forward-looking information, whether as a result of new information or future events or results, except to the extent required by applicable securities laws.
About Neo Performance Materials
Neo manufactures the building blocks of many modern technologies that enhance efficiency and sustainability. Neo's advanced industrial materials – magnetic powders, rare earth magnets, magnetic assemblies, specialty chemicals, metals, and alloys – are critical to the performance of many everyday products and emerging technologies. Neo's products fast-forward technologies for the net-zero transition. The business of Neo is organized along three segments: Magnequench, Chemicals & Oxides and Rare Metals. Neo is headquartered in Toronto, Ontario, Canada; with corporate offices in Greenwood Village, Colorado, United States; Singapore; and Beijing, China. Neo has a global platform that includes manufacturing facilities located in China, Germany, Canada, Estonia, Thailand and the United Kingdom, as well as one dedicated research and development centre in Singapore. For more information, please visit www.neomaterials.com.
SOURCE Neo Performance Materials, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
29 minutes ago
- Cision Canada
Arizona Metals Announces 2025 Mineral Resource Estimate for Kay Mine Project
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/ TORONTO, June 30, 2025 /CNW/ - Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) (the "Company" or "Arizona Metals") is pleased to announce an initial Mineral Resource Estimate ("MRE") for its 100% owned Kay Mine Project (the "Kay Project") located in Yavapai County, Arizona. Highlights of the Kay Project MRE are as follows: The underground MRE includes 9.28 million tonnes grading 1.39 g/t Au, 27.6 g/t Ag, 0.97% Cu, 0.33% Pb, and 2.39% Zn in the Indicated category, and 0.86 million tonnes grading 1.06 g/t Au, 15.4 g/t Ag, 0.87% Cu, 0.20% Pb, and 1.68% Zn in the Inferred category, at a base-case cut-off grade of 1.00 % CuEq. Copper equivalent MRE grades are 9.28 million tonnes @ 3.18% CuEq in the Indicated category and 0.86 million tonnes @ 2.44% CuEq in the Inferred category. Quality Asset: High grade, with good geometry and continuity suitable for bulk underground mining methods. Camp Potential: The initial MRE sits within less than 5% of the 10-km long strike of folded prospective host rocks in the Kay Project. Infill Potential: This initial MRE has clear potential to expand between existing drill holes within the deposit, and to upgrade Inferred resource. Expansion Potential: The deposit remains open for expansion beyond this initial MRE both along strike and at depth. Continued Advancement: Following the completion of additional metallurgical testwork, a preliminary economic assessment ("PEA") is planned for release in the second half of 2025. The Company is delivering and executing on all of its previously-stated goals for 2025 and looks forward to continuing the development of the Company's strong assets. Duncan Middlemiss, President and CEO of Arizona Metals, comments:" The release of our initial Mineral Resource Estimate marks a major milestone for Arizona Metals and validates not only the scale, but more importantly, the quality of the Kay Project. With over 650 million pounds of copper equivalent in the Indicated category alone—and with the deposit remaining open in multiple directions—we see significant opportunity for expansion through continued drilling. We believe this resource represents just the beginning. With a strong treasury and a PEA on track for release later this year, we're excited to advance the Kay Project toward becoming one of the top undeveloped VMS projects in the U.S." Table 1. Kay Mine Property Underground Mineral Resource Estimate at a Base-case Cut-off Grade of 1.00% CuEq, June 17, 2025 Kay Mine Property Mineral Resource Estimate Notes: (1) The effective date of the Kay Mine Project Mineral Resource Estimate (MRE) is June 17, 2025. This is the close-out date for the final mineral resource drilling database. (2) The mineral resource was estimated by Allan Armitage, Ph.D., P. Geo. of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Armitage conducted site visits to the Kay Mine property on two occasions, on October 25-26, 2023, and April 7-8, 2024. The mineral resource was peer reviewed by Ben Eggers, MAIG, of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Eggers conducted a site visit to the Kay Mine property on May 30, 2025. (3) The classification of the current MRE into Indicated and Inferred mineral resources is consistent with current 2014 CIM Definition Standards - For Mineral Resources and Mineral Reserves. (4) All figures are rounded to reflect the relative accuracy of the estimate and numbers may not add due to rounding. (5) All mineral resources are presented undiluted and in situ, constrained by continuous 3D wireframe models (considered mineable shapes), and are considered to have reasonable prospects for eventual economic extraction. (6) Mineral resources which are not mineral reserves do not have demonstrated economic viability. An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that most Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. (7) The Kay Mine Project MRE is based on a validated drill hole database which includes data from 234 surface diamond drill holes completed between 2020 and May 2025. The drilling totals 133,912 m (including wedge holes). The resource database totals 11,533 assay intervals representing 14,006 m of data. (8) Grades for Au, Ag, Cu, Pb and Zn are estimated for each mineralization domain using 1.50 m capped composites assigned to that domain. To generate grade within the blocks, the inverse distance squared (ID 2) interpolation method was used for all domains. (9) Average density values were assigned to each domain based on a database of 2,307 samples. (10) Based on the size, shape, and orientation of the deposit, it is envisioned that the deposits may be mined using underground bulk mining methods such as Longhole Stoping. The MRE is reported at a base case cut-off grade of 1.00 % CuEq. The mineral resource grade blocks are quantified above the base case cut-off grade and within the constraining mineralized wireframes (considered mineable shapes). (11) The underground base case cut-off grade of 1.00% CuEq considers metal prices of $4.10/lb Cu, $1.00/lb Pb, $1.35/lb Zn, $2,200/oz Au and $26/oz Ag, metal recoveries of 92% for Cu, 76% for Pb, 85% for Zn, 76% for Au and 75% for Ag, a mining cost of US$49.00/t rock and processing, treatment and refining, transportation and G&A cost of US$29/t mineralized material. (12) The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. Table 2. Kay Mine Property Underground Mineral Resource Estimate at Various CuEq% Cut-off Grades, June 17, 2025 (1) Underground mineral resources are reported at a base case cut-off grade of 1.00% CuEq. Values in this table reported above and below the base case cut-off grades should not be misconstrued with a Mineral Resource Statement. The values are only presented to show the sensitivity of the block model estimate to the base case cut-off grade. (2) All values are rounded to reflect the relative accuracy of the estimate, and numbers may not add due to rounding. The Company is fully-funded to complete its planned drilling through the end of 2025 and is on track to deliver a PEA in the second half of 2025, for the Kay Project. G Mining Services Inc. ("G Mining") has audited the MRE and has been engaged to complete the PEA. The current phase of resource drilling is complete, and the Company has mobilized the two drill rigs to the Kay North Extension target, to be followed by drilling on the North-Central and Western Targets at the Kay Project. These areas will be drilled for the first time from newly-permitted and strategically-positioned drill pads, designed to optimize targeting and access. The Company plans 10,000 m of exploration drilling at these targets with holes ranging from 300 m to 900 m in depth. The Company has chosen these high-priority targets based on analysis of geologic, geochemical, and geophysical exploration data generated to date on the project. Additionally, 5,000 m of reverse circulation drilling is planned at the Company's Sugarloaf Peak Gold Project (the "Sugarloaf Peak Project") in La Paz County, Arizona. Drilling and road-construction contractors have been chosen for the Sugarloaf Peak Project, and the Company is preparing to mobilize crews during Q3. About Arizona Metals Corp Arizona Metals Corp owns 100% of the Kay Project in Yavapai County, which is located on 1669 acres of patented and BLM mining claims and 193 acres of private land that are not subject to any royalties. The Kay Project is a steeply dipping VMS deposit that has been defined from a depth of 60 m to at least 900 m. It is open for expansion on strike and at depth. The Company also owns 100% of the Sugarloaf Peak Project, in La Paz County, which is located on 4,400 acres of BLM claims. The Sugarloaf Peak Project is a heap-leach, open-pit target and has a historic estimate of "100 million tons containing 1.5 million ounces gold" at a grade of 0.5 g/t (Dausinger, N.E., 1983, Phase 1 Drill Program and Evaluation of Gold-Silver Potential, Sugarloaf Peak Project, Quartzsite, Arizona: Report for Westworld Inc.) The historic estimate at the Sugarloaf Peak Project was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a Qualified Person before the historic estimate can be verified and upgraded to a current mineral resource. A Qualified Person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Qualified Person and Quality Assurance/Quality Control The mineral resource was estimated by Allan Armitage, Ph.D., P. Geo. of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Armitage conducted site visits to the Kay Mine property on two occasions, on October 25-26, 2023, and April 7-8, 2024. The mineral resource was peer reviewed by Ben Eggers, MAIG, of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Eggers conducted a site visit to the Kay Mine property on May 30, 2025. All of Arizona Metals' drill sample assay results have been independently monitored through a quality assurance/quality control ("QA/QC") protocol which includes the insertion of blind standard reference materials and blanks at regular intervals. Logging and sampling were completed at Arizona Metals' core handling facilities located in Phoenix and Black Canyon City, Arizona. Drill core was diamond sawn on site and half drill-core samples were securely transported to ALS Laboratories' ("ALS") sample preparation facility in Tucson, Arizona. Sample pulps were sent to ALS's labs in Vancouver, Canada, and Reno, Nevada, for analysis. Gold content was determined by fire assay of a 30-gram charge with ICP finish (ALS method Au-AA23). Silver and 32 other elements were analyzed by ICP methods with four-acid digestion (ALS method ME-ICP61a). Over-limit samples for Au, Ag, Cu, and Zn were determined by ore-grade analyses Au-GRA21, Ag-OG62, Cu-OG62, and Zn-OG62, respectively. ALS Laboratories is independent of Arizona Metals Corp. and its Vancouver and Reno facilities are ISO 17025 accredited. ALS also performed its own internal QA/QC procedures to assure the accuracy and integrity of results. Parameters for ALS' internal and Arizona Metals' external blind quality control samples were acceptable for the samples analyzed. Arizona Metals is not aware of any drilling, sampling, recovery, or other factors that could materially affect the accuracy or reliability of the data referred to herein. The qualified person who devised and monitored the Company's QA/QC program is David Smith, CPG, a qualified person as defined in National Instrument43-101 – Standards of Disclosure for Mineral Projects. Mr. Smith is the Vice-President, Exploration of the Company. Mr. Smith supervised the drill program and verified the data disclosed, including sampling, analytical, and QA/QC data underlying the technical information in this news release, including reviewing the reports of ALS, methodologies, results, and all procedures undertaken for quality assurance and quality control in a manner consistent with industry practice, and all matters were consistent and accurate according to his professional judgement. There were no limitations on the verification process. Disclaimer This press release contains statements that constitute "forward-looking information" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements contained in this press release include, without limitation, statements regarding the expansion potential of the Kay Project, statements regarding drill results and future drilling at the main Kay Project, and at additional targets including the North, North-Central and Western Targets at the Kay Project, and expansion drilling targets on the Kay Project, statements regarding drilling and other exploration activity on the Sugarloaf Peak Gold Project, statements regarding completion of a PEA in H2 2025 or at all, statements regarding execution of the Company's plans for 2025 and the achievement of targeted milestones. In making the forward- looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: availability of the Company to stay well funded; delay or failure to receive required permits or regulatory approvals; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward- looking statements or otherwise. SOURCE Arizona Metals Corp.
Cision Canada
2 hours ago
- Cision Canada
Hisense Showcases AI Technology Strength with "AI YOUR LIFE" Message at FIFA Club World Cup 2025™
QINGDAO, China, June 30, 2025 /CNW/ -- Hisense, a leading brand in global consumer electronics and home appliances, is showcasing its AI leadership at the FIFA Club World Cup 2025™ with the bold pitch-side message "AI YOUR LIFE," reflecting the brand's vision of human-centric innovation through intelligent technology. As one of the earliest consumer tech brands to explore AI, Hisense is integrating intelligent features across its product portfolio. Today, at the core of Hisense's intelligent ecosystem is the Hi-View AI Engine X—its most powerful AI processor yet. Powered by deep neural networks, it learns and adapts like a human brain, optimizing picture and sound across all content, from fast-paced sports to cinematic films and immersive gaming. Driving the next generation of ULED AI TVs, Hi-View AI Engine X powers four key pillars: AI Picture for lifelike contrast, color, and motion; AI Sound for adaptive clarity and immersive acoustics; AI Scenario for automatic mode switching; and AI Energy for top performance with greater efficiency. Together, they create a more immersive, intelligent way to enjoy every match, goal, and moment on screen. Beyond the screen, Hisense expands smart connectivity in the home through ConnectLife. From AI-guided cooking to personalized laundry care, users enjoy seamless, scenario-based intelligence. The PureFlat Smart Series refrigerator, with its 21-inch screen, serves as a convenient hub to manage appliances with ease. For Hisense, whether it's screen or appliance, the essence is home — and the essence of home is love. Now enhanced by AI, that belief evolves—technology becomes more intuitive, responsive, and emotional. As global audiences celebrate football's finest moments, Hisense invites everyone to "Own the Moment" with intelligent products that understand, adapt, and inspire. About Hisense Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV volume shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023- Q12025). As the first official partner of the FIFA Club World Cup 2025™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.
Cision Canada
3 hours ago
- Cision Canada
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025. MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Riverview, Michigan: The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). This facility is a vital element of ADCelerate™, supplying the payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025. Lexington, Kentucky: The Lexington site is Piramal Pharma's dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. As a critical component of Piramal Pharma's integration, the site provides fill/finish services for all integrated programs, including ADCelerate™ projects. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027. Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. "We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe," said Nandini Piramal, Chairperson, Piramal Pharma. "As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. "ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide." The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well." Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world." Commerce Lexington President and CEO, Bob Quick, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive." Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
